Oppenheimer analyst Jeff Jones downgraded Y-mAbs Therapeutics (YMAB) without a price target to Perform from Outperform after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics
- Y-mAbs Therapeutics downgraded to Hold from Buy at Truist
- Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline
- Y-mAbs Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street